Stryker Corporation (SYK)
NYSE:SYK
Want to see SYK full AI Analyst Report?
Top Page
Stryker
(NYSE:SYK)
Select Model
Select Model
Rating:63Neutral
Price Target:
$314.00
▼(-8.54% Downside)
Action:ReiteratedDate:05/04/26
The score is supported primarily by strong underlying financial performance (scaling revenue, solid profitability, and rising free cash flow). It is held back by very weak technicals (deeply oversold and below key moving averages) and a rich valuation (high P/E with only a modest yield). The latest earnings call is a moderate positive overall due to reaffirmed full-year guidance, but near-term cyber-related disruption and margin pressure temper confidence.
Positive Factors
Scale & Margin
Material revenue scale and consistently high gross margins reflect a broad, higher‑value medical device portfolio and pricing/policy leverage. Scale supports R&D, distribution, and cross‑sell economics, helping sustain margins and ROE even as specific lines cycle.
Negative Factors
High Absolute Debt
Material absolute debt raises refinancing and interest‑rate sensitivity despite better debt/equity trends. Elevated leverage constrains flexibility for opportunistic investments and amplifies earnings exposure to rising rates and higher other expense.
Read all positive and negative factors
Positive Factors
Negative Factors
Scale & Margin
Material revenue scale and consistently high gross margins reflect a broad, higher‑value medical device portfolio and pricing/policy leverage. Scale supports R&D, distribution, and cross‑sell economics, helping sustain margins and ROE even as specific lines cycle.
Read all positive factors
Stryker (SYK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$111.96B
Dividend Yield0.95%
Average Volume (3M)2.12M
Price to Earnings (P/E)42.2
Beta (1Y)0.63
Revenue Growth8.84%
EPS Growth16.34%
CountryUS
Employees53,000
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)8.73
Shares Outstanding382,984,250
10 Day Avg. Volume1,890,050
30 Day Avg. Volume2,115,674
Financial Highlights & Ratios
PEG Ratio5.16
Price to Book (P/B)5.99
Price to Sales (P/S)5.35
P/FCF Ratio31.36
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue4.88
Enterprise Value/Gross Profit7.66
Enterprise Value/Ebitda22.48
Forecast
1Y Price Target
$394.32Price Target Upside14.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering23
EPS Forecast (FY)15
Revenue Forecast (FY)$27.33B
Stryker Business Overview & Revenue Model
Company Description
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint re...
How the Company Makes Money
Stryker makes money primarily by selling medical devices, implants, capital equipment, and related consumables and services to healthcare providers.
Key revenue streams
1) Implantable and procedure-based products (recurring, volume-driven): A lar...
Stryker Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across different regions, revealing where Stryker is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Breaks down revenue across different regions, revealing where Stryker is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Data provided by:
The Fly
The FlyStryker Earnings Call Summary
Earnings Call Date:Apr 30, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Positive
The call mixed a significant near-term operational setback—the late-quarter cyber incident that materially distorted Q1 results, pressured margins and reduced EPS—with several strong positives: rapid operational recovery, record Mako installations and robust robotic momentum, continued healthy underlying demand, strategic reorganization (Ortho Tech), active M&A (AVS) and maintained full-year guidance (organic sales growth 8.0%–9.5%, adjusted EPS $14.90–$15.10). Management expects most lost Q1 sales to be realized through the rest of the year, with catch-up skewed to the back half, and emphasized customer/employee support and successful recovery efforts.Positive Updates
Organic Sales Growth Despite Disruption
Q1 organic net sales growth of 2.4% worldwide, with 1.9% growth in the U.S. and 3.9% internationally. Management emphasized underlying demand remained healthy across businesses despite the cyber incident.
Negative Updates
Significant Cyber Incident Disruption
Late-quarter cyber incident caused global operational disruption, delayed shipments and revenue recognition, wiped devices, and required multi-week recovery efforts. The incident materially distorted Q1 results and delayed normal reporting detail.
Read all updates
Q1-2026 Updates
Positive
Negative
Organic Sales Growth Despite Disruption
Q1 organic net sales growth of 2.4% worldwide, with 1.9% growth in the U.S. and 3.9% internationally. Management emphasized underlying demand remained healthy across businesses despite the cyber incident.
Read all positive updates
Company Guidance
Stryker reiterated full‑year guidance despite the late‑quarter cyber incident, forecasting organic net sales growth of 8.0%–9.5% and full‑year adjusted net earnings per share of $14.90–$15.10, with adjusted other income and expense expected to be about $420 million and a full‑year effective tax rate of 15%–16%; management said most first‑quarter disruption will be recovered through the year with some revenue catch‑up in Q2 and more in H2, and that pricing should be modestly positive (with a slightly favorable FX/interest rate tailwind if rates hold and some anticipated tariff improvement). For Q1 they reported 2.4% organic sales growth (U.S. 1.9%, international 3.9%), pricing +0.3%, FX +1.6%, adjusted EPS of $2.60 (down $0.24 or 8.5% YoY), adjusted gross margin 63.6% (‑190 bps) and adjusted operating margin 21.1% (‑180 bps); YTD cash from operations was $581 million, gross debt/EBITDA was ~2.1x, and management continues to target healthy margin and cash conversion (roughly 70%–80% FCF conversion).Stryker Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
74
Positive
Cash Flow
77
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 25.27B | 25.12B | 22.59B | 20.50B | 18.45B | 17.11B |
| Gross Profit | 16.09B | 16.07B | 13.98B | 12.49B | 11.04B | 10.71B |
| EBITDA | 5.48B | 6.31B | 4.94B | 5.06B | 4.02B | 3.61B |
| Net Income | 3.34B | 3.25B | 2.99B | 3.17B | 2.36B | 1.99B |
Balance Sheet | ||||||
| Total Assets | 46.29B | 47.84B | 42.97B | 39.91B | 36.88B | 34.63B |
| Cash, Cash Equivalents and Short-Term Investments | 2.96B | 4.10B | 4.49B | 3.05B | 1.93B | 3.02B |
| Total Debt | 14.22B | 14.86B | 14.12B | 13.49B | 13.53B | 12.90B |
| Total Liabilities | 23.99B | 25.42B | 22.34B | 21.32B | 20.27B | 19.75B |
| Stockholders Equity | 22.30B | 22.42B | 20.63B | 18.59B | 16.62B | 14.88B |
Cash Flow | ||||||
| Free Cash Flow | 4.57B | 4.28B | 3.49B | 3.14B | 2.04B | 2.74B |
| Operating Cash Flow | 5.38B | 5.04B | 4.24B | 3.71B | 2.62B | 3.26B |
| Investing Cash Flow | -915.00M | -4.87B | -3.00B | -962.00M | -2.92B | -859.00M |
| Financing Cash Flow | -3.93B | 113.00M | -525.00M | -1.59B | -749.00M | -2.37B |
Stryker Technical Analysis
Neutral
343.32
Price Trends
352.73
Negative
355.53
Negative
366.25
Negative
Market Momentum
-2.01
Negative
51.54
Neutral
54.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYK, the sentiment is Neutral. The current price of 343.32 is above the 20-day moving average (MA) of 334.63, below the 50-day MA of 352.73, and below the 200-day MA of 366.25, indicating a neutral trend. The MACD of -2.01 indicates Negative momentum. The RSI at 51.54 is Neutral, neither overbought nor oversold. The STOCH value of 54.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SYK.
Stryker Risk Analysis
Stryker disclosed 29 risk factors in its most recent earnings report. Stryker reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Stryker Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $47.97B | 30.46 | 10.61% | ― | 13.81% | 22.90% | |
68 Neutral | $83.24B | 17.42 | 15.40% | ― | 17.44% | 74.36% | |
67 Neutral | $99.63B | 28.29 | 9.54% | 2.76% | 6.88% | 9.06% | |
64 Neutral | $16.02B | 18.51 | 5.78% | 1.05% | 9.23% | -14.66% | |
63 Neutral | $111.96B | 42.22 | 15.22% | 0.95% | 8.84% | 16.34% | |
62 Neutral | $150.32B | 41.63 | 11.43% | 1.88% | 6.59% | -53.44% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
SYK
Stryker
292.33
-88.06
-23.15%
ABT
Abbott Laboratories
86.30
-44.97
-34.26%
BSX
Boston Scientific
56.00
-48.80
-46.56%
EW
Edwards Lifesciences
83.20
8.16
10.87%
MDT
Medtronic
77.60
-3.00
-3.72%
ZBH
Zimmer Biomet Holdings
82.83
-10.33
-11.08%
Stryker Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Stryker Addresses and Contains Recent Cybersecurity Incident
Negative
Mar 23, 2026
Stryker disclosed that a cybersecurity incident identified and reported to the U.S. SEC on March 11 and 12, 2026 disrupted its corporate network, including its Microsoft environment, but current findings indicate no malicious activity directed at ...
Business Operations and Strategy
Stryker Reports Cybersecurity Incident Disrupting Global IT Systems
Negative
Mar 12, 2026
On March 11, 2026, Stryker Corporation identified a cybersecurity incident that disrupted its global Microsoft-based information technology environment, and on March 12, 2026, Chief Information Security Officer Dave Nathans briefed customers and c...
Business Operations and StrategyFinancial Disclosures
Stryker Investigates Cybersecurity Incident Disrupting IT Systems
Negative
Mar 12, 2026
On March 11, 2026, Stryker Corporation identified a cybersecurity incident that disrupted its global Microsoft information technology environment and affected access to certain systems and business applications. The company activated its cybersecu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.